SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Lidak Pharm. [LDAKA]
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: luis a. garcia who wrote (930)3/3/1998 10:04:00 AM
From: Henry Volquardsen  Read Replies (1) of 1115
 
Looks like HealthMed is gone.

LIDAK PHARMACEUTICALS ANNOUNCES TERMINATION OF DISCUSSIONS
3/3/98 9:17

With HealthMed, Inc.

LA JOLLA, Calif., March 3 /PRNewswire/-- LIDAK Pharmaceuticals
(Nasdaq: LDAKA) announced today that it has received correspondence from
HealthMed, Inc. unilaterally terminating all discussions with respect to a
loan transaction. William Jenkins, Chairman of the Special Committee of
independent directors of LIDAK formed to evaluate the HealthMed proposal,
noted that the termination letter was received on the eve of the date
HealthMed had scheduled to conduct due diligence at the Company and shortly
after LIDAK had requested diligence of HealthMed and its financing source
relating to their ability to perform.
Mr. Jenkins expressed disappointment at HealthMed's decision to terminate
discussions. "We were looking forward to determining whether a HealthMed
transaction could be achieved consistent with the best interests of LIDAK
shareholders. Although we remain open to productive dialogue with HealthMed,
the LIDAK Board of Directors intends to pursue aggressively other means to
realize the value of LIDAKOL and the Company's other potential products."
LIDAK Pharmaceuticals is developing therapeutic products designed to treat
virally caused diseases, allergies and asthma, inflammatory disorders and
cancer. LIDAK's topical drug for the treatment of recurrent oral facial
herpes, LIDAKOL, was recently submitted to the United States Food and Drug
Administration for marketing approval.

SOURCE LIDAK Pharmaceuticals
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News